2023
Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer
Check D, Jackson B, Reeder-Hayes K, Dinan M, Faherty E, Kwong J, Mehta S, Spees L, Wheeler S, Wilson L, Lam C. Characteristics, healthcare utilization, and outcomes of patients with HER2-low breast cancer. Breast Cancer Research And Treatment 2023, 203: 329-338. PMID: 37875669, DOI: 10.1007/s10549-023-07142-4.Peer-Reviewed Original ResearchConceptsHER2-low breast cancerBreast cancerHealthcare utilizationOutcomes of patientsRetrospective cohort studyStage IV diseaseStage IV patientsMetastatic breast cancerNew treatment guidelinesRate of hospitalizationBreast cancer patientsClinical characteristicsCohort studyHazard ratioIV patientsOverall cohortPositive diseaseTreatment guidelinesIHC 0Utilization outcomesTreatment optionsCancer patientsSurvival differencesPatientsStage IV
2012
Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003
Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003. Journal Of Clinical Oncology 2012, 30: 2725-2730. PMID: 22753917, DOI: 10.1200/jco.2011.40.4392.Peer-Reviewed Original ResearchConceptsPositron emission tomographyOverall survivalStage migrationMedicare beneficiariesAdvanced diseasePET useEnd Results-Medicare dataEmission tomographyProportion of patientsStage IV diseaseCell lung cancerSelection biasUpstaging of diseaseGreater overall survivalStage-specific survivalStudy criteriaLung cancerSurvival AssociatedImproved outcomesRetrospective analysisStage distributionNSCLCPatientsDiseaseSurvival